Hemodynamic effects of sacubitril/valsartan in patients with reduced left ventricular ejection fraction over 24 months: a retrospective study
The effects of sacubitril/valsartan in patients with chronic heart failure with reduced ejection fraction (HFrEF) were recently reported. However, the hemodynamic impact of this well-established treatment in patients with HFrEF has been poorly systematically researched.
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
30 March 2022
|
| In: |
American journal of cardiovascular drugs
Year: 2022, Volume: 22, Issue: 5, Pages: 535-544 |
| ISSN: | 1179-187X |
| DOI: | 10.1007/s40256-022-00525-w |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s40256-022-00525-w Verlag, kostenfrei, Volltext: https://link.springer.com/content/pdf/10.1007/s40256-022-00525-w.pdf?pdf=button |
| Author Notes: | Mohammad Abumayyaleh, Jonathan Demmer, Carina Krack, Christina Pilsinger, Ibrahim El-Battrawy, Michael Behnes, Assem Aweimer, Andreas Mügge, Siegfried Lang, Ibrahim Akin |
| Summary: | The effects of sacubitril/valsartan in patients with chronic heart failure with reduced ejection fraction (HFrEF) were recently reported. However, the hemodynamic impact of this well-established treatment in patients with HFrEF has been poorly systematically researched. |
|---|---|
| Item Description: | Gesehen am 18.09.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1179-187X |
| DOI: | 10.1007/s40256-022-00525-w |